Treatment options for Alzheimer’s disease (AD) are limited because of the inability of drugs to cross the blood–brain barrier (BBB). A promising strategy to overcome this obstacle is the use of nanoparticles (NPs). Previously, we showed that intraperitoneal administration of liposomes functionalized with phosphatidic acid and an ApoE-derived peptide (mApoE-PA-LIP) reduces brain beta-amyloid (Aβ) burden and ameliorates impaired memory in AD mice. Here, we investigated lung administration as an alternative, non-invasive NP delivery route for reaching the brain. Our results show that mApoE-PA-LIP were able to cross the pulmonary epithelium ([14C]-PA permeability = 6.5 ± 2.0 × 10–6 cm/min) in vitro and reach the brain (up to 0.6 μg PA/g brain) following in vivo intratracheal instillations. Lung administration of mApoE-PA-LIP to AD mice significantly decreased total brain Aβ (–60%; p < 0.05) compared to untreated mice. These results suggest that pulmonary administration could be exploited for brain delivery of NPs designed for AD therapy. [Figure not available: see fulltext.]

Sancini, G., DAL MAGRO, R., Ornaghi, F., Balducci, C., Forloni, G., Gobbi, M., et al. (2016). Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer’s disease murine model. NANO RESEARCH, 9(7), 2190-2201 [10.1007/s12274-016-1108-8].

Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer’s disease murine model

SANCINI, GIULIO ALFREDO
Primo
;
DAL MAGRO, ROBERTA
;
RE, FRANCESCA
2016

Abstract

Treatment options for Alzheimer’s disease (AD) are limited because of the inability of drugs to cross the blood–brain barrier (BBB). A promising strategy to overcome this obstacle is the use of nanoparticles (NPs). Previously, we showed that intraperitoneal administration of liposomes functionalized with phosphatidic acid and an ApoE-derived peptide (mApoE-PA-LIP) reduces brain beta-amyloid (Aβ) burden and ameliorates impaired memory in AD mice. Here, we investigated lung administration as an alternative, non-invasive NP delivery route for reaching the brain. Our results show that mApoE-PA-LIP were able to cross the pulmonary epithelium ([14C]-PA permeability = 6.5 ± 2.0 × 10–6 cm/min) in vitro and reach the brain (up to 0.6 μg PA/g brain) following in vivo intratracheal instillations. Lung administration of mApoE-PA-LIP to AD mice significantly decreased total brain Aβ (–60%; p < 0.05) compared to untreated mice. These results suggest that pulmonary administration could be exploited for brain delivery of NPs designed for AD therapy. [Figure not available: see fulltext.]
Articolo in rivista - Articolo scientifico
Alzheimer’s disease; ApoE-derived peptide; liposomes; lung administration; nanoparticles;
ApoE-derived peptide lung administration nanoparticles Alzheimer’s disease liposomes
English
2190
2201
12
Sancini, G., DAL MAGRO, R., Ornaghi, F., Balducci, C., Forloni, G., Gobbi, M., et al. (2016). Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer’s disease murine model. NANO RESEARCH, 9(7), 2190-2201 [10.1007/s12274-016-1108-8].
Sancini, G; DAL MAGRO, R; Ornaghi, F; Balducci, C; Forloni, G; Gobbi, M; Salmona, M; Re, F
File in questo prodotto:
File Dimensione Formato  
NanoResearch 2016.pdf

Solo gestori archivio

Descrizione: articolo principale
Dimensione 1.94 MB
Formato Adobe PDF
1.94 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/111552
Citazioni
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 14
Social impact